Doseology Sciences Inc. develops consumer products around precision-controlled oral stimulant pouch technologies. News about Doseology Sciences centers on its non-nicotine, caffeine-based Feed That Brain Energy Pouches, direct-to-consumer distribution in the United States, pilot production, brand development, and the use of oral pouch formats for controlled stimulant delivery.
Company updates also cover OTCQB trading under DOSEF, capital-markets communications, governance changes, and regulatory strategy for oral pouch products, including formulation, data generation, PMTA preparation, and post-market compliance themes tied to regulated consumer stimulant categories.
Doseology (DOSED) filed its Annual Information Form (AIF) for the fiscal year ended June 30, 2025 on SEDAR+ to consolidate disclosure on business, strategy, risk factors, governance, and capital structure. The AIF aims to improve investor transparency and accessibility by combining information previously spread across multiple documents. The filing does not announce any financing or offering and is process-driven to maintain disclosure readiness and potential short-form prospectus eligibility under NI 44-101.
Doseology (ticker: DOSED) announced a strategic partnership with McKinney Regulatory Science Advisors to advance regulatory execution and commercial readiness for Doseology's oral pouch product portfolio. McKinney will advise on formulation strategy, data generation, Pre-market Tobacco Product Application (PMTA) preparation, labeling, and post-market compliance to support nicotine and nicotine-analogue pouch formats. The engagement aims to accelerate FDA pathway navigation, align R&D and manufacturing validation with regulatory expectations, strengthen IP and dose-consistency controls, and establish post-market surveillance and adverse-event reporting frameworks.
The collaboration is positioned to move Doseology from development toward regulated-market readiness while emphasizing consumer safety and regulatory-aligned product design.
Doseology (PINK: DOSEF) launched an Investor Communications Initiative on December 1, 2025 to strengthen disclosure, expand investor engagement, and support its commercial and capital‑markets strategy. The program includes a 3‑month engagement with Guerilla Capital (Dec 1, 2025–Feb 28, 2026) for $30,000 CAD, and a digital media agreement with Maynard Communications (commencing Dec 1, 2025; term listed to May 31, 2026) for $200,000 CAD. The company said the initiative will align reporting with governance standards, broaden retail and institutional visibility, and support commercialization of its oral stimulant platform. Regulatory disclosures state both firms or their principals currently hold Doseology securities and engagements are not at arm’s length; compensation is not tied to stock performance.
Doseology (PINK: DOSEF) announced that its wholly owned U.S. subsidiary, Doseology USA Inc., executed a confidential manufacturing agreement with a leading North American production partner on November 13, 2025. The partner operates an FDA-registered, GMP-certified, ISO 9001:2015 facility and offers end-to-end manufacturing for oral stimulant pouches including formulation, ingredient sourcing, pouch filling, packaging, and logistics. Doseology says the agreement provides scalable production from pilot runs to high-volume commercial output and establishes the operational and regulatory foundation to move from R&D toward market readiness in North America.
Summary not available.
Doseology Sciences Inc. (OTCQB: DOSEF) announced the resignation of CEO Ralph Olson and Director David Lutz, effective March 31, 2023. Pratik Patel, the Company’s CFO, has been appointed as interim CEO. The Company has granted 2,450,000 stock options at an exercise price of $0.10 per share. The strategic alternatives process initiated on January 23, 2023, is still ongoing, with further updates to be provided as necessary. This transition occurs amid Doseology's ongoing focus on developing functional fungi products aimed at addressing mental health challenges.
Doseology Sciences Inc. (OTCQB: DOSEF) announced the appointment of Pratik (Tiki) Patel as the new Chief Financial Officer, effective March 3, 2023. Patel, a Chartered Professional Accountant with over 15 years of experience, replaces Peter Geh, who was thanked for his contributions. The CEO, Ralph Olson, expressed enthusiasm for Patel's financial expertise, emphasizing its potential positive impact on the company. Doseology focuses on mental health and wellness by developing innovative nutraceutical products utilizing functional fungi. The company aims to address mental health issues through its product line, available on its official website.
Doseology Sciences Inc. (CSE: MOOD, OTCQB: DOSEF) announced the termination of its lease in Vernon, British Columbia, ceasing its application for a Dealer's License. CEO Ralph Olson cited the limited market for psilocybin products and regulatory slowdowns as reasons for this decision. The company will shift focus to retail channels for its functional mushroom products. Additionally, the Board is conducting a strategic review to explore options like mergers or acquisitions. Harbir Toor resigned, with David Lutz and Pratik Patel appointed as directors.
Doseology Sciences Inc. has announced its approval for uplisting to the OTCQB Venture Market, effective July 6, 2022. Starting today, their shares will trade under the symbol DOSEF in the United States. This uplisting aims to enhance visibility and liquidity for investors. Doseology, which focuses on mental health and wellness through innovative products derived from functional fungi and plants, will continue trading on the Canadian Securities Exchange under the symbol MOOD and on the Frankfurt Stock Exchange as VU7.
Doseology Sciences Inc. has announced that its common shares are now approved for trading on the OTC Pink Open Market in the US under the symbol DOSEF. They will continue trading on the Canadian Securities Exchange and Frankfurt Stock Exchange under symbols MOOD and VU7 respectively. Furthermore, the Company applied for uplisting to the OTCQB Market. Doseology's shares also received eligibility for book-entry services through the Depository Trust Company, which is expected to enhance trading liquidity and accessibility for American investors, facilitating easier transactions.